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Abstract In the last years, the treatment of multiple sclerosis
(MS) patients with natalizumab has been associated with the
occurrence of progressive multifocal leukoencephalopathy
(PML) caused by human polyomavirus JC (JCV). Here, we
have shown a significant correlation between patients with JC
viruria and positive JC-specific antibody response and pa-
tients without JCV-specific antibodies after 1 year of
natalizumab (p=0.0006). Furthermore, JCV-specific quantita-
tive PCR on urine and plasma samples, collected at the enroll-
ment (t0) and every 4 months (t1, t2, t3) in the first year and at
two time points (t4 and t5) in the second year of natalizumab
treatment, indicated the prevalence of JC viremia rather than
JC viruria only in the second year of treatment (p=0.04).
Moreover, the analysis of JCV non-coding control region
(NCCR) sequences in peripheral blood mononuclear cells of
patients with JC-specific antibodies after 12 natalizumab in-
fusions (t3) revealed the presence of rearranged sequences,
whereas the prevalence of genotypes 1A, 1B, and 4 was de-
tected in these patients by VP1 sequence analysis. In
summary, JC viruria evaluation seems to be useful to identify
early those patients who do not already develop a humoral
immune response against JCV. It may also be interesting to
study the JCVNCCR rearrangements since they could give us
new insights on the onset of neuro-invasive viral variants.
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Introduction
In the last years, many immune-mediated diseases such as
multiple sclerosis (MS) have been managed using biological
drugs. Nevertheless, the use of these drugs was soon associated
with the onset of progressive multifocal leukoencephalopathy
(PML). In 2005, two patients with MS (Kleinschmidt-
DeMasters and Tyler 2005; Langer-Gould et al. 2005) and
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one with Crohn’s disease (CD) (Van Assche et al. 2005) were
reported as the first cases of PML development after the treat-
ment with natalizumab (Tysabri®, Biogen Idec, Elan
Pharmaceuticals). PML is a demyelinating disease of the cen-
tral nervous system (CNS) caused by polyomavirus JC (JCV)
lytic infection of oligodendrocytes. JCV is a DNA neurotropic
virus isolated in 1971 from the brain of a patient with PML
(Padgett et al. 1971). Ninety percent of the worldwide adult
population has antibodies against JCV, with 27 % of healthy
individuals that asymptomatically release virions in the urine
(Brew et al. 2010; Kean et al. 2009). The early and the late
coding regions of JCV genome are highly conserved and can
be associated with viral genotypes and subtypes of specific
geographical areas (Agostini et al. 2001). In contrast, the viral
non-coding control region (NCCR) is highly variable and char-
acterized by determinants of neurotropism and neurovirulence.
Rearranged NCCR sequences were observed during the host
immunosuppression, and they correlated with a poor prognosis
in PML patients. The incidence of PML has increased during
the global HIVepidemic in the 1980s (Tan andKoralnik 2010),
although the introduction of combination antiretroviral therapy
(cART) in the treatment of HIV infection has overturned this
trend, with a reduction of PML onset among HIV patients.
However, in recent years, PML cases are increasing among
patients with immune-mediated diseases treatedwithmonoclo-
nal antibodies (mAb) (Weissert 2011), and as of January 2015,
514 cases of PML had been reported among the 132,600 MS
patients treated with natalizumab worldwide, with a fatality
rate of about 20–25 % (TYSABRI Safety Update 2015). The
estimated risk of natalizumab PML-associated is 11.1 cases per
1000 patients (95 % CI 8.3 to 14.5) when the three main risk
factors are present: (1) JCV-specific antibodies, (2) previous
use of immunosuppressants, and (3) 25 months of natalizumab
treatment (Bloomgren et al. 2012; Sørensen et al. 2012).
Natalizumab interferes with lymphocyte trafficking through
the blood–brain barrier (BBB) by blocking the interaction of
very late antigen 4 (VLA4) with adhesion molecule type 1 on
vascular cells (VCAM-1). This blocking seems to result in
decreased immunosurveillance and JCV reactivation from la-
tency (Berger and Houff 2009; Tan et al. 2010; Zohren et al.
2008). To date, specific biomarkers of PML risk assessment
are not available and no correlation has been reported between
the JC viral load in blood and/or urine and the PML onset
(Andreoletti et al. 2002; Marzocchetti et al. 2009; Rudick
et al. 2010; Tan et al. 2010). However, a new enzyme immu-
noassay (STRATIFY JCV®) has been distributed by the same
pharmaceutical company producing natalizumab to discrimi-
nate JCV-specific serostatus (Gorelik et al. 2010) and viral
DNA detection in urine samples has been found useful for a
more accurate stratification of PML risk in patients treated with
natalizumab (Laroni et al. 2012). In fact, it has been suggested
that JCV viruria could allow identification of JCV-positive
patients with undetectable JCV-specific antibodies (Mancuso
et al. 2012). Nevertheless, the exact mechanism by which
natalizumab promotes the PML pathogenesis has not yet been
well defined, but it strongly depends on a reduced immune
surveillance of the central nervous system (Coisne et al.
2009; Kivisakk et al. 2009; Stuve et al. 2006). Despite the
JCV lytic infection of oligodendrocytes in individuals with
PML, JCV can latently persist in a variety of cell types includ-
ing hematopoietic precursor CD34+ cells and B cells in the
bone marrow, brain, tonsils, and the bloodstream
(Marzocchetti et al. 2009; Tan et al. 2010). It is also important
to note that the development of PML in immunocompromised
patients appears to be limited to rearrangements of the viral
NCCR and the consequent enhancing of viral gene expression
mediated by the binding of specific cellular transcription fac-
tors on the JCV NCCR (Marshall and Major 2010). Therefore,
in this study, we have investigated the trend of JCV replication
in cohorts of relapsing–remitting MS (RRMS) patients at a
different stage of natalizumab treatment: at the baseline with
the number of natalizumab infusions equal to 0 (t0), during the
first 12 infusions (<12 months), and after more than 12 months
of treatment (>12 months). Three aspects of JCV replication
have been evaluated: (1) the monitoring of JCV viral load by
real-time quantitative PCR (Q-PCR) in different biological
samples collected from the cohort at specific sampling times;
(2) the analysis of possible rearrangements of the JCV NCCR,
in order to identify possible mutations in the binding sites for
specific transcription factors; and (3) the sequence analysis of
the JCV VP1 gene, in order to establish a possible correlation
between a specific JCV genotype/subtype and patients with
RRMS treated with natalizumab.
Materials and methods
Features of enrolled patients and study schedule
Patients affected by RRMS, referred to the Department of
Neurology and Psychiatry of the University of Rome
“Sapienza” from March 2012 to March 2014, and with the
following number of infusions of natalizumab, have been
enrolled:
– Twenty-two patients (mean age±stand. dev. 30.6±6.8;
mean months of illness±stand. dev. 84±85.7; mean
Expanded Disability Status Scale (EDSS)±stand. dev.
1.9 ± 1.3) were enrolled before treatment with
natalizumab (t0: baseline or 0 infusions) and a total of
22 samples of whole blood in EDTA and 22 urine sam-
ples have been collected. Of these 22 patients, 2 had
discontinued therapy for allergic reaction to the biologic
after 2 natalizumab infusions and 5 showed poor compli-
ance (Table 1). The remaining 15 patients (mean age±
stand. dev. 33±7.7; mean months of illness±stand. dev.
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112.4±100.3; mean EDSS±stand. dev. 1.9±1.3) have
been monitored during the first year of treatment with
natalizumab (follow-up <12months) as follows: 1 sample
of whole blood in EDTA and 1 tube of urine have been
collected after 4 (t1), 8 (t2), and 12 (t3) infusions of
natalizumab, respectively. Forty-five samples of whole
blood in EDTA and 45 urine samples have been tested
(Table 1).
– In addition, 18 whole blood samples in EDTA (4 collect-
ed at t1, 4 at t2, and 10 at t3) and 14 urine samples (3
collected at t1, 3 at t2, and 8 at t3) have been collected
from other 15 patients with RRMS with the number
of infusions ranging from 4 to 12 (<12 months)
(Table 1).
– Finally, 38 samples of whole blood in EDTA and 34 urine
samples were collected from 22 patients with RRMS
(mean age±stand. dev. 38.2±7.6; mean months of ill-
ness±stand. dev. 100±79.2; mean EDSS±stand. dev.
2.2±1.1) with the number of infusions ranging from 13
to 24 (t4). Moreover, 18 samples of whole blood in EDTA
and 14 urine samples have been collected from 11 pa-
tients with RRMS (mean age±stand. dev. 39.7±10.6;
mean months of illness±stand. dev. 75.6±44.9; EDSS
mean±stand. dev. 2.2±1.0) with the number of infusions
higher than 24 (t5) (>12 months) (Table 1).
All patients satisfied the Italian Agency of Drug criteria for
natalizumab treatment (AIFA 2010). The therapeutic program
consisted of 300 mg intravenous (IV), infused over 1 h, every
month.
After the activation of the STRATIFY JCV® service, sup-
ported byBiogen Idec, the assessment of specific anti-JC virus
antibodies in serum of the enrolled subjects was performed at
t0 and t3 (Gorelik et al. 2010).
At each follow-up visit, disease activity has been assessed
by the Kurtzke Expanded Disability Status Scale (EDSS),
with values ranging from 0 (normal neurological examination)
to 10 (bedridden patient). EDSS is a standardized composite
neurological examination, developed for multiple sclerosis
clinical research (Kurtzke 1983). The magnetic resonance im-
aging (MRI) has been performed at the beginning of therapy
and eventually during treatment, depending on the clinical
course of each patient. Finally, the lumbar puncture has been
performed only in the case of neuro-radiological or clinical
alterations in the presence of JCV replication in plasma or
peripheral blood mononuclear cells (PBMCs). Each patient,
properly informed, has signed informed consent, in order to
take part in the study.
DNA extraction
DNAhas been extracted from a total of 141 plasma, 129 urine,
and 141 PBMC samples collected at the specified time-points.
DNA extraction has been conducted on 500 μL of urine sam-
ple using the DNeasy® Blood & Tissue Kit (QIAGEN, S.p.A,
Italy). Blood samples have been collected in 4-mL
Vacuntainer® tubes containing EDTA (BD Becton
Dickinson, S.p.A, Italy) and centrifuged at 3500 rpm for
10 min and DNA was extracted from 200 μL of plasma by
the DNeasy® Blood & Tissue Kit (QIAGEN, S.p.A, Milan,
Table 1 Clinical features of RRSM patients
Baseline (0 infusion) t0 <12 months >12 months
4–12 infusions (t1–t3) 13–24 infusions (t4) >24 infusions (t5)
F/M (n) 8/14 13/17 17/5 9/2
Total 22 30 22 11
STRATIFY JCV®a +/− t0 4/18 5/25
STRATIFY JCV®a +/− t3 – 13/17 6/16 3/8
Mean age (±stand. dev.) 30.6 (±6.8) 35 (±8.4) 38.2 (±7.6) 39.7 (±10.6)
Mean of months of disease (±stand. dev.) 84 (±85.7) 107 (±89.7) 100 (±79.2) 75.6 (±44.9)
Mean EDSSb (±stand. dev.) 1.9 (±1.3) 2.1 (±1.0) 2.2 (±1.1)
2 (1–4)
2.2 (±1.0)
2 (1–4)
No therapyc (n) 9 9 5 1
Interferonc (n) 13 18 12 8
Glatimer acetatec (n) – 3 5 2
F female, M male, n number of patients, stand. dev. standard deviation
a STRATIFY JCV® : two-step virus-like particle-based enzyme-linked immunosorbent assay (ELISA) was performed at t0 and t3 (1 year of treatment), to
detect specific anti-JC virus antibodies in serum of the enrolled subjects (Gorelik et al. 2010)
b EDSS: Kurtzke Expanded Disability Status Scale, with values ranging from 0 (normal neurological examination) to 10 (bedridden patient) (Kurtzke 1983)
c Therapy before starting with natalizumab treatment
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Italy). Peripheral blood mononuclear cells (PBMCs) were iso-
lated from whole blood using a standard Ficoll Hypaque den-
sity gradient centrifugation (Bøyum et al. 1991). The viable
leukocytes have been determined by trypan blue exclusion,
and PBMC DNA extraction has been obtained on 106 cells
by the QIAmp® DNA Blood Kit (QIAGEN, S.p.A, Milan,
Italy). All extracted DNA samples have been stored at
−20 °C until use.
JCV T-Ag real-time PCR (Q-PCR)
Q-PCR has been performed to detect and quantify the JCV
genome copy numbers using a 7300 Real-Time PCR System
(Applied Biosystems, USA) and following published protocol
(Delbue et al. 2008). This Q-PCR was specific for a 54-bp
amplicon in the JCV T antigen region. The viral load results
have been reported as the mean of two positive reactions for
each sample, and the JCV DNA load in urine and plasma
specimens has been expressed as genome equivalents (gEq)/
milliliter of sample and as genome equivalents (gEq)/106 cells
of sample for PBMCs. In each Q-PCR section, negative and
positive controls have been considered. The positive control
consisted of serial dilutions (range 105–102 gEq/mL) of a
plasmid containing the entire JCV genome, used to fit a stan-
dard curve. Finally, the amount of DNA in PBMC samples has
been normalized by a specific TaqMan PCR for the house-
keeping gene glyceraldehyde-3-phosphate-dehydrogenase
(GAPDH, accession no. J04038). Results have been consid-
ered acceptable only in the presence of GAPDH positivity
(Costa et al. 2009).
JCV NCCR PCR
Two pairs of primers that anneal to invariant regions flanking
the NCCR of JCV (Pietropaolo et al. 2003) have been used in
a nested-PCR. BKTT1 (5′-AAG GTC CAT GAG CTC CAT
GGATTC TTC C-3′) and BKTT2 (5′-CTA GGT CCC CCA
AAA GTG CTA GAG CAG C-3′) amplified a 724-bp DNA
fragment in JCV Mad-1 (Flaegstad et al. 1991). JC1 (5′-CCT
CCACGCCCTTACTACTTCTGAG-3′) and JC2 (5′-AGC
CTGGTGACAAGCCAAAACAGCTCT-3′) amplified an
inner sequence of the first PCR product, generating a fragment
of 308 bp (Markowitz et al. 1993). PCR products have been
analyzed on 2 % agarose gels by ethidium bromide staining.
JCV VP1 PCR
A 215-bp sequence has been amplified from the viral protein 1
(VP1) gene using primers JLP-15 (5′-ACA GTG TGG CCA
GAA TTC ACT ACC-3′) and JLP-16 (5′-TAA AGC CTC
CCC CCC AAC AGA AA-3′) (Agostini et al. 2001). After
denaturation at 95 °C for 9 min, 40 cycles at 95 °C for 40 s,
63 °C for 40 s, and 72 °C for 40 s have been concluded with a
final extension at 72 °C for 7 min. PCR products have been
analyzed using 2 % electrophoresis agarose gel stained by
ethidium bromide (Monaco et al. 2001).
Sequencing of JCV NCCR and VP1 regions
PCR products corresponding to JCV NCCR and VP1 regions
have been purified with the QIAquick PCR purification kit,
according to QIAGEN protocol (Pietropaolo et al. 2003).
DNA sequencing has been conducted in service (BioFab re-
search s.r.l., Rome, Italy). All NCCR sequences were com-
pared to the prototype Mad-1 (NCBI Reference Sequence:
NC_001699.1) (Frisque et al. 1984) and archetype CY
(Yogo et al. 1990), whereas the sequences obtained from am-
plification of the VP1 region were analyzed on the basis of
single nucleotide polymorphisms (SNPs) used to classify the
JCV genotypes/subtypes (Jobes et al. 2001). Sequence align-
ments were performed with ClustalW2 at the EMBL-EBI
website using default parameters (ClustalW2 2014).
Data analysis
Data were shown as mean±standard deviation or medians and
ranges. If the Z test indicated a non-normal distribution, non-
parametric tests such as Mann–Whitney U test and Kruskal–
Wallis test have been used. Categorical data were analyzed by
χ2 test and Student’s t test. p values <0.05 were considered
significant.
Results
Evaluation of JCV-specific serum antibodies by STRA
TIFY JCV® and JCV load by Q-PCR in biological
samples collected at t0 from 22 patients with RRMS
Twenty-two samples of whole blood in EDTA and 22 samples
of urine were collected, and JCV-specific antibodies were ob-
served in serum of 4 patients (STRATIFY JCV® positive)
while the other 18 patients were tested STRATIFY JCV® neg-
ative. Among the 4 STRATIFY® JCV-positive patients, viral
DNA was detected exclusively in plasma (2.84 log10 gEq/
mL) and in PBMCs (2.07 log10 gEq/106 cells) of 1 patient
(Table 2). By contrast, in 18 STRATIFY JCV®-negative pa-
tients, JC viruria was found in 4/18 samples with a median
viral load of 4.38 log10 gEq/mL (range 3.48–4.58), while JC
viremia was observed in 2/18 patients with a median viral load
of 3.02 log10 gEq/mL (range 2.70–3.20). Moreover, in these
18 patients, JCV DNAwas detected in 2 samples of PBMCs
with a median viral load of 3.42 log10 gEq/106 cells (range
1.95–3.72) (Table 2). At t0, no statistically significant differ-
ence and correlation were observed between viruria and/or
viremia and STRATIFY® JCV results in these patients.
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Evaluation of JC viral load by Q-PCR in biological
samples of 15 RRMS patients with follow-up in the first
year of treatment with natalizumab (follow-up
<12 months)
At t0, JCV-specific antibodies were detected only in 1/15 pa-
tient, while the number of STRATIFY JCV®-positive patients
rose to 7/15 at t3. Regarding the detection of JCV DNA by Q-
PCR in urine, in samples collected at t0, JC viruria was ob-
served in 4/15 STRATIFY JCV®-negative patients at t0.
These patients developed anti-JCV antibodies during the first
year of treatment with natalizumab, becoming STRATIFY
JCV® positive at t3. The median viral load in urine samples
at t0 was 4.38 log10 gEq/mL (range 3.48–4.58), while after
4 months of treatment with natalizumab (t1), this value was
4.11 log10 gEq/mL (range 2.00–6.01). At t2 (after 8
natalizumab infusions), the number of patients with JCV
DNA in the urine increased from 4 to 5, with the finding of
JC viruria in 1 patient which resulted STRATIFY JCV® neg-
ative both at t0 and at t3. This patient subsequently became
negative for JCV DNA in urine at t3 (after 12 natalizumab
infusions). In conclusion, a persistent viruria throughout
follow-up was observed in 4/15 RRMS patients. Overall,
compared to t0, the median viral load in the urine increased
up to 5.18 log10 gEq/mL (range 3.77–5.65) at t2 and up to
5.63 log10 gEq/mL (range 5.29–5.94) at t3, and this increase
was statistically significant (p=0.05) (Fig. 1).
Regarding the JCV DNA detection in plasma samples, JC
viremia was found at t0 in only 2 patients with a negative
STRATIFY JCV® and a value of the median viral load of
2.95 log10 gEq/mL (range 2.70–3.21). However, these 2 pa-
tients with viremia at t0 were negative at t1, while other 2
patients (STRATIFY JCV® negative at t0 and STRATIFY
JCV® positive at t3) with persistent viruria throughout the
follow-up showed JCV DNA in plasma with a median viral
load of 2.15 log10 gEq/mL (range 1.61–2.69). Finally at t2, all
15 RRMS patients were negative for JCV DNA in plasma
whereas, at t3, only 1 patient (STRATIFY JCV® negative both
at t0 and t3) showed JCV load in plasma (1.86 log10 gEq/mL)
and in PBMCs (1.11 log10 gEq/106 cells) (Fig. 1).
Regarding the PBMCs, at t0, JCV DNA was detected in
PBMCs of 2 patients, STRATIFY JCV® negative at t0 and
STRATIFY JCV® positive t3, with a mean value of viral DNA
copies of 2.82 log10 gEq/106 cells (range 1.92–3.72). One of
these two patients showed persistent viruria throughout the fol-
low-up. At t1, the viral DNAwas found in the PBMCs of only 1
patient (1 log10 gEq/106 cells) with viremia at the same time of
sampling and persistent viruria throughout the follow-up. Finally,
at t2, in only 1 patient was JCVDNAdetected in PBMCs, with a
viral load of 2.16 log10 gEq/106 cells (data not shown).
Statistical analysis of these data highlighted that the median
number of genome equivalents of JCV detected in urine was
significantly higher than that observed in plasma (p=0.047)Ta
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(Fig. 1) and in PBMC (p=0.029) (data not shown). Finally,
2/15 patients did not perform two natalizumab infusions, due
to a concomitant urinary infection by Escherichia coli and a
clinically worsening of RRMS with a positive STRATIFY
JCV® at t3.
Evaluation of JC viral load by Q-PCR in biological
samples of 30 RRMS patients with the number
of natalizumab infusions ranging from 4 to 12
(<12 months)
In addition to the 15 patients described above, in this cohort
were also enrolled another 15 patients with the mean number
of infusions between 4 and 12 (<12 months). From these 15
patients, 18 whole blood samples in EDTA (4 obtained at t1,
4 at t2, and 10 at t3) and 14 urine samples (3 obtained at t1, 3 at
t2, and 8 at t3) were collected and the JC viral load was
assessed by q-PCR. Regarding the blood samples, the results
showed that all 18 plasma samples were negative for viral
DNA, whereas only 1/18 PBMC sample, obtained from
a STRATIFY JCV®-positive patient at t3, showed a JC
viral load of 1.95 log10 gEq/106 cells. On the other
hand, concerning the 14 urine samples, in only one
sample from 1 STRATIFY JCV®-negative patient at t3
was JC viruria observed with a viral load value of 6.04
log10 gEq/106 cells.
Among the 59 urine samples collected in this cohort, 45
belonged to the 15 RRMS patients with a complete follow-up
in the first year of natalizumab treatment and 14 belonged to
15 RRMS patients with the number of natalizumab infusions
ranging from 4 to 12 (<12months). The results obtained byQ-
PCR showed that 14/59 urine samples were positive to
the JCV DNA and 12 of these 14 positive urine sam-
ples were collected from 4 patients with a negative
STRATIFY JCV® at t0 and a positive STRATIFY
JCV® at t3. The median value of these 12 samples with
JC viruria was 5.33 log10 gEq/mL (range 2–6.01). In
the remaining 2 urine samples, taken from two patients
with a negative STRATIFY JCV® both at t0 and t3, the
mean value of the JC viral load was 5.74 log10 gEq/mL
(range 3.77–6.04) (Table 3).
Regarding the whole blood in EDTA samples, 63 plasma
samples and 63 PBMC samples were collected. 3/63 plasma
and 4/63 PBMC samples resulted JCV DNA positive. In par-
ticular, the mean JC viremia was 2.42 log10 gEq/mL (range
1.61–2.69) in 2 plasma samples collected from 2 patients with
a positive STRATIFY JCV® at t3 and a persistent JC viruria
during the first year of natalizumab treatment. Moreover, a
third patient, with negative STRATIFY JCV® at t0 and t3,
showed JCV DNA in both plasma (1.86 log10 gEq/mL) and
PBMCs (1.11 log10 gEq/106 cells) (Table 3). Finally, in 3
PBMC samples taken from three patients, with a positive
STRATIFY JCV® at t3, a median value of 1.95 log10 gEq/
106 cells was quantified (Table 3).
The statistical analysis, performed by the χ2 test, has
allowed verification of a statistically significant associa-
tion between the number of JCV DNA-positive urine
samples and a positive STRATIFY JCV® at t3 with
respect to the number of JCV DNA-positive urine sam-
ples and a negative STRATIFY JCV® at t3 (p=0.0006).
A relative risk (RR) of viral reactivation with urinary
shedding equal to 2.57 (95 % CI 1.61–4.09) was also
estimated (Table 3). Therefore, the analysis of results
allowed us to conclude that the detection of JC viruria
by Q-PCR may represent a predictor of JCV reactivation
in the first year of natalizumab treatment.
Fig. 1 JC viremia and viruria in 15 RRSM patients during the first
12 months of natalizumab treatment (follow-up <12 months). Serial
urine and plasma samples were performed at t0 (baseline: 0
natalizumab infusions) and every 4 months for 1 year (t1: 4 infusions;
t2: 8 infusions; t3: 12 infusions). There was no statistically significant
difference between JC viremia values recorded at t0 and the other values
observed at each time of follow-up. On the other hand, JC viruria values
observed at t2 were significantly higher than those observed at t0. Finally,
at each time of follow-up, the JC viremia values were always significantly
lower with respect to the JC viruria values. Statistical analysis was
performed using nonparametric tests and significance was set for
a p value <0.05
658 J. Neurovirol. (2015) 21:653–665
Evaluation of JC viral load by Q-PCR in biological
samples of RRMS patients with the number
of natalizumab infusions >12 (>12 months)
In this cohort were enrolled 22 patients with the number of
natalizumab infusions ranging from 13 to 24 (t4) and 11 pa-
tients with the number of natalizumab infusions >24 (t5)
(Table 1). Thirty-eight samples of whole blood in EDTA and
34 urine samples were collected from the 22 patients at t4.
Finally, 18 samples of whole blood in EDTA and 14 urine
samples were collected from the 11 patients at t5 listed above.
In these two groups of patients, there was no statistically sig-
nificant difference or correlation between the clinical and de-
mographic data, the results of JCV DNA detection in the
different biological samples, and the outcomes of STRA
TIFY JCV®. Therefore, all results were related to the cohort
of RRMS patients with the number of natalizumab infusions
greater than 12. It was important to note that 6 patients (1
patient with a positive STRATIFY JCV® at t3 and 5 patients
with a negative STRATIFY JCV® at t3) underwent sample
collection at both t4 and t5. Therefore, the total number of
patients with more than 13 natalizumab infusions was 27.
From these 27 patients, 48 urine, 56 plasma, and 56 PBMC
samples were collected. 8/48 urine samples (median JC viruria
5.11 log10 gEq/mL; range 2.94–6.67), 9/56 plasma samples
(median JC viremia 3.01 log10 gEq/mL; range 1.52–4.72),
and 6/56 PBMC samples (median copies number 2.39
log10 gEq/106 cells; range 1.48–4.11) were positive for JCV
DNAThese data are summarized in Table 4.
Comparison of JC viremia and viruria in RRMS patients
with infusion number equal to 0 (t0: baseline), ranging
from 4 to 12 (<12 months) and >12 (>12 months)
Comparing the values of JC viruria and viremia (log10 gEq/
mL) obtained from 22 RRMS patients at t0, 30 RRMS pa-
tients treated with natalizumab for less than 12months, and 27
RRMS patients treated for more than 12 months, it was ob-
served that the median values of JC viremia were always
lower than that of JC viruria (p=0.001) (Table 5 and Fig. 2).
In addition, it was assessed that patients treated with
natalizumab for more than 12 months had a relative risk of
1.71 to develop JC viremia with respect to patients treated
with less than 12 months (p=0.04) (Table 5).
Sequence analysis of JCV NCCR and VP1 in biological
samples positive for viral DNA
The sequence analysis of JCV NCCR in biological samples
positive for viral DNAwas carried out by direct sequencing of
PCR products. In the group of RRMS patients treated with
natalizumab for less than 12 months (<12 months) was found
an archetype CY-like structural organization of NCCR, withTa
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217 G to A nucleotide transition in box F, in 68 % of biolog-
ical samples analyzed, while in the remaining 32 %, NCCR
rearranged sequences were identified. In 4 urine samples col-
lected respectively at t0, t1, t2, and t3 from a single RRMS
patient with a positive STRATIFY JCV® at t3, a sequence of
NCCR, characterized by a duplication of the binding site for
the cellular transcription factor NF-1 in box F, was found
without the 217 G to A nucleotide transition in the same
box. Furthermore, both in plasma and PBMC samples collect-
ed from a RRMS patient with negative STRATIFY JCV® at
t3, a 208 A to G nucleotide transition in box F of an archetype
CY-like structural organization of NCCR, with involvement
of the cellular transcription factor NF-1 binding site,
was found. Finally, in 4 PBMC samples belonging to
4 different RRMS patients with positive STRATIFY
JCV® at t3, the following structural organizations of
NCCR were found:
– One sequence with an archetype CY-like structural orga-
nization and two characteristic point mutations: the 37 T
to G nucleotide transversion within the binding site for
the cellular transcription factor Spi-B in box B and the
217 G to A nucleotide transition in box F
– One sequence with an archetype CY-like structural orga-
nization but with the deletion of box D and the two point
mutations described above
– Two sequences of rearranged NCCR, characterized by
the deletion of box B, the 37 T to G nucleotide
transversion within the binding site for the cellular tran-
scription factor Spi-B, the duplication of box C, and the
presence of box D (Fig. 3)
Finally, in RRMS patients treated with natalizumab for more
than 12 months (>12 months), an archetype CY-like structural
organization of NCCR, with the 217 G to A nucleotide transi-
tion in box F, was found in all biological samples analyzed,
with the exception of a sequence that presented an archetype
CY-like organization characterized by the 37 T to G nucleotide
transversion within the binding site for the cellular transcription
factor Spi-B in box B and the 217 G to A nucleotide transition
in box F (Fig. 3). This sequence was found in the PBMC sam-
ple of a patient with positive STRATIFY JCV® at t3.
Regarding the sequence analysis of JCV VP1, in order to
determine the viral genotype/subtype, in RRMS patients treat-
ed with natalizumab for less than 12 months (<12 months),
genotypes 1A (40 %) and 1B (50 %) were observed.
Moreover, in the patient with a positive STRATIFY JCV®
and rearranged NCCR in the urine, a JCV co-infection by
genotypes 1A and 2C was observed, while only genotype
1Awas found in the plasma of the same patient. In the cohort
of patients with RRMS treated with natalizumab for more than
12 months (>12 months), genotypes 1A (31 %), 1B (46 %),
and 4 (23 %) were always found in the urine and/or plasma
positive for JCV DNA.
Discussion
The pathogenesis of natalizumab-associated PML onset is still
poorly understood, and viral and/or host factors are not avail-
able in order to detect those natalizumab-treated patients with
high risk to develop PML (Mancuso et al. 2012). A clear
association between JC viremia and/or viruria and PML has
Fig. 2 JC viremia and viruria in
22 RRMS patients with the
infusion number equal to 0 (t0),
30 RRMS patients treated with
natalizumab for less than
12 months (<12 months), and 27
RRMS patients treated for more
than 12 months (>12 months).
The values of JC viremia were
always significantly lower than
those of JC viruria in each group
of RRMS patients analyzed. All
the information related to JCV
load values is reported in Table 5.
Statistical analysis was performed
using non-parametric tests
and the significance fixed for
a p value <0.05
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not been also established. In order to stratify the risk of PML
onset among RRMS patients treated with natalizumab, a new
ELISA assay for the detection of JCV-specific antibodies
(JCV STRATIFY®) has been designed. Although this method
was extremely sensitive, some authors have found a false-
negative rate equal to 2.5 % in a cohort of RRMS patients
with viral DNA in the urine but no JCV-specific antibodies
in serum (Gorelik et al. 2010).
In this study, the data obtained from STRATIFY JCV®
were not always correlated with those obtained by Q-PCR:
in fact, the presence of viral DNA in urine samples at baseline
(t0) preceded the antibody detection in serum samples after 12
natalizumab infusions (negative STRATIFY JCV® at t0 and
positive STRATIFY JCV® at t3). These data were in agree-
ment with those of other studies reported in the literature,
which showed an asymptomatic JCV reactivation at the level
of the urinary tract in patients with RRMS treated with less
than 12 natalizumab infusions (Chen et al. 2009; Sadiq et al.
2010). Therefore, as suggested by other authors (Laroni et al.
2012), the analysis of the results allowed us to conclude that in
RRMS patients, the trend of JC viruria may represent a pre-
dictor of viral reactivation in the first 12 months of treatment
with natalizumab also in cases where the STRATIFY JCV®
has given a negative result.
Finally, the results obtained suggest that JCV replication in
the urinary epithelium, with concomitant presence of JC viruria,
seems not to be due to a lack of infection control by the T cells,
but rather to a reduction of lymphocyte diapedesis induced by
natalizumab. In fact, as already suggested by other authors, the
failure of localization of T lymphocytes at the level of the in-
fected renal epithelium seems to abolish the viral antigen pre-
sentation by APCs (Chen et al. 2009; Mancuso et al. 2012).
Fig. 3 Sequences of JCV NCCR found in biological samples of RRMS
patients treated with natalizumab. The nucleotide sequences of JCV
NCCR were shown from the core of the replication origin (ori) up to
the start codon of the gene leader (agnoprotein) of the late viral genes.
In A, the nucleotide numbering of the archetype CY sequence, isolated
from Yogo and colleagues in 1990, is shown in bold gray. In F, the
nucleotide numbering was based on the NCCR sequence of the PML-
associated variant Mad-1, sequenced by Frisque and colleagues in 1984,
and the nucleotide number is indicated in bold black. In B, the NCCR
sequence was characterized by a duplication of cellular transcription
factor NF-1 binding site in box F, with loss of the 217 G to A (G→A)
nucleotide transition in the same box. It was found in 4 JCV DNA-
positive urine samples collected at t0, t1, t2, and t3, respectively, from 1
patient with positive STRATIFY JCV®. In C, a rearranged NCCR was
reported, characterized by the deletion of box B with a T to G nucleotide
transversion within the cellular transcription factor Spi-B binding site, the
duplication of box C, and the presence of box D. It was isolated from
PBMC samples of 2 RRMS patients that were STRATIFY JCV® positive
after 1 year of treatment with natalizumab (t3). InD, the sequence with an
archetype CY-like structural organization was reported but with the
deletion of box D and two characteristic point mutations: the 37 T to G
(T→G) nucleotide transversion within the binding site for the cellular
transcription factor Spi-B in box B and the 217 G to A nucleotide
transition in box F. Finally, in E, the sequence model IS is illustrated,
consisting of a single sequence from 98 bp, as reported by Jensen and
Major JCVNCCR organization (Jensen andMajor 2001). The cladogram
was performed by software ClustalW2 (Clustal-W2)
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Some authors have also observed a decrease in JCV-specific
cell-mediated response, after in vitro stimulation of PBMC
from RRMS patients with a pool of JCV VP1-specific antigen
after 6 and 12 natalizumab infusions, respectively. This de-
crease was found to be more pronounced in JC viremic patients
than in non-viremic, and these results led the authors to con-
clude that natalizumab has a direct negative effect on the pro-
duction of IFN-γ by JCV-specific T cells after about 1 year of
treatment (12 natalizumab infusions). Therefore, the reduction
of JCV-specific cellular response seems to favor the reactivation
of JCV in the kidney and its subsequent diffusion in the blood
(Chen et al. 2009). Moreover, data obtained from this study
showed a higher prevalence of negative STRATIFY JCV® pa-
tients who develop JCV viremia following the administration of
the number of infusions of natalizumab greater than 12.
Therefore, the absence of JCV-specific antibodies in these pa-
tients led us to assume that humoral immunity may not be able
to keep under control the viral replication at the systemic level.
Regarding the study of NCCR sequences, in the group of
RRMS patients treated with natalizumab for less than
12 months (<12 months), an archetype CY-like structural or-
ganization of NCCR with 217 G to A nucleotide transition in
box F was found in 68 % of biological samples analyzed,
while in the remaining 32 % analyzed sequences, rearranged
NCCR were identified. In 4 urine samples collected respec-
tively at t0, t1, t2, and t3 from 1 RRMS patient with a positive
STRATIFY JCV® at t3, a sequence of NCCR, characterized
by a duplication of the binding site for the cellular transcrip-
tion factor NF-1 in box F, was found without the 217 G to A
nucleotide transition in the same box. Finally, in 2 PBMC
samples, belonging to 2 different RRMS patients with positive
STRATIFY JCV® at t3, a rearranged NCCR was found and it
was characterized by the deletion of box B, the 37 T to G
nucleotide transversion within the binding site for the cellular
transcription factor Spi-B, the duplication of box C, and the
presence of box D. In particular, the last described sequence
showed that rearranged viral strains might reverse into the
bloodstream throughout latency in PBMCs. In particular, this
rearranged sequence showed a deletion of the B box with 37 T
to G nucleotide transversion in the hematopoietic transcription
factor Spi-B binding site, duplications of box C, and the CRE
element binding site. This rearrangement was similar to the
sequence of neurotropic variants found in patients with PML
by some authors (Ferenczy et al. 2012; Marzocchetti et al.
2007). In particular, the potential neurovirulence of this
rearranged sequence was conferred by the repeat of the CRE
element binding site in box C, a specific enhancer of JCV
replication in glial cells (Kumar et al. 1996), and by formation
of the high-affinity binding site for the transcription factor
hematopoietic Spi-B, the expression of which is elevated in
hematopoietic cell lines (CD34+ cells and B cells), where the
JC virus establishes latency (Lindberg et al. 2008; Major
2010). In addition, as widely described in the literature, it
seems that the use of natalizumab may promote the mobiliza-
tion of CD34+ cells and B cells infected with JCV. Therefore,
these cells may be considered carriers of the virus to the CNS
(Major 2009; Neumann et al. 2009). In particular, the 37 T to
G transversion nucleotide transforms the typical binding site
for the cellular factor Spi-B (5′-AAAAGGGAAGGTA-3′) of
the non-pathogenic JCV variant (archetype CY) in that char-
acteristic of PML-associated JCV variant Mad-1 (5′-AAAA
GGGAAGGGA-3′), and this could result in viral replication
and NCCR rearrangement (Marshall et al. 2012). However,
further studies are needed to understand what are the cellular
pathways involved in the expression of the hematopoietic
transcription factor Spi-B and how these pathways are regu-
lated by the production of specific cytokines involved in the
control of viral infection (Bellizzi et al. 2013).
Finally, the detection of the 217 G to T nucleotide transition
in box F at the level of the binding site for the cellular tran-
scription factor NF-1 is in agreement with literature data,
which reported this point mutation in the European JCV
strains (Agostini et al. 1996). However, in 4 urine samples
collected respectively at t0, t1, t2, and t3 from 1 RRMS patient
with a positive STRATIFY JCV® at t3, a sequence of NCCR,
characterized by a duplication of the binding site for the cel-
lular transcription factor NF-1 in box F, was found without the
217 G to A nucleotide transition in the same box. It was noted
that NF-1 increased the expression of early and late genes of
JCV in glial cells, permissive to viral replication (Monaco
et al. 2001; Shinohara et al. 1997). Moreover, the tandem
repeated NF-1 binding sites on JCV NCCR could be consid-
ered determinants of specificity for glial cells and therefore
determinants of neurotropism. Therefore, the duplication of
the binding site for the cellular transcription factor NF-1 in
box F, observed in NCCR isolated from urine samples, sug-
gests that the natalizumab-induced alterations of
immunosurveillance could determine a selective pressure on
JCV variants with determinants of neurotropism and increased
neurovirulence.
Sequence analysis of the viral VP1 was performed on sam-
ples of urine and plasma in order to determine the genotypes
of JCV circulating in patients treated with natalizumab. The
prevalence of genotypes 1A and 1B, most commonly found in
European populations (Agostini et al. 2001), was observed. In
the two patients with RRMS who, after 1 year of treatment
with natalizumab had rearranged sequences in PBMC of the
NCCR, were found genotype 1A and 1B, respectively.
In conclusion, although it has not been possible to identify a
real correlation between the presence of variants neurovirulent
and treatment with natalizumab, this study showed that during
the spread of the virus into the host, you go to select particular
sequences of the NCCR of JCVand that treatment with mono-
clonal antibody seems to have a role in the selection of these
variants. However, it remains unclear what the viral and host
factors are behind this selection process.
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Conclusion
In conclusion, for a more accurate stratification of the risk of
PML in patients treated with natalizumab, the JC viruria assay
would seem to be useful in identifying those patients with
JCV-specific humoral response that is not yet detectable. In
addition, the results of this study show the importance of the
analysis of rearrangements of the NCCR of JCV. Currently,
we do not know the significance of our finding regarding JCV
NCCR analysis and, therefore, further investigation is war-
ranted Moreover, the study of the molecular mechanisms in-
volved in cell latency and reactivation of JCV in peripheral
blood cells is of substantial importance in order to identify the
missing pieces in the puzzle of the pathogenesis of PML. It is
therefore essential to focus attention on cellular pathways,
finely regulated by the host’s immune system, leading to re-
activation of the virus under conditions of immunosuppres-
sion, since the treatment of PML with anti-viral drugs has
proved to be ineffective.
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